About this trial
This observational, multinational study assesses the feasibility of speech and self-report data collection across six languages for Artificial Intelligence (AI)-driven relapse risk estimation in psychosis. Over 12 months, patients at risk of relapse and healthy controls will provide weekly speech recordings and self-report data for automated analysis. Risk scores will be stored but not shared with treating clinicians. Independent clinical evaluations ensure data quality and validation. The study lays the foundation for future Clinical Decision Support System (CDSS) research and explores novel speech markers for relapse prediction while minimizing participant burden.
Eligibility criteria
Qualifiers
Between 18 and 65 years old.
Subjects must be able to provide informed consent (IC).
Participants must have provided signed informed consent prior to enrollment.
Participants should not take prescription drugs regularly.
Disqualifiers
Any history of major diseases (e.g., cardiovascular, neurological, metabolic, renal, hepatic, respiratory or speech disorders).
Recreational drug use or psychiatric disorders due to use of alcohol.
Depression, anxiety, or other psychiatric disorders.
Family history of depression, anxiety, or other psychiatric disorders.
Trial design
Treatments tested in this trial
- Weekly online speech assessments via a smartphone app collect speech and self-report data. Recordings are securely transferred and analyzed by an AI-based backend to calculate relapse risk scores.
Treatment groups
Sponsors and collaborators
Philipp Homan
Lead sponsor
University of Zurich
Sponsor institution